Estonia strengthened its digital ties with the Kingdom of Saudi Arabia (KSA) as the Estonian business delegation, together with Minister of Justice and Digital Affairs Liisa-Ly Pakosta, visited the ...

Laura Mercier announced today that it has launched the luxury beauty shopping app for Apple Vision Pro, created in partnership with immersive shopping platform and visionOS developer Obsess. Obsess ...

Bristol Myers Squibb (BMY) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

Bristol Myers Squibb & Co BMY released topline data Monday from its Phase 2 TRANSCEND FL trial of Breyanzi (lisocabtagene maraleucel) for relapsed or refractory indolent B-cell non-Hodgkin lymphoma.

Bristol Myers Squibb (BMY) ended the recent trading session at $60.62, demonstrating a +1.59% swing from the preceding day's closing price. The stock's performance was ahead of the S&P 500's daily ...

Ratings for Bristol-Myers Squibb BMY were provided by 9 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The following table encapsulates their recent ...

Bristol-Myers Squibb's Cobenfy launch shows strong initial sales and broad Medicaid/Medicare coverage, supporting its blockbuster potential in schizophrenia and future label expansions.

Citi analyst Geoff Meacham maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) today and set a price target of $65.00. The company’s shares closed yesterday at $57.42.